2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Hererra A, Friedberg J, Friedman D, Schwartz C, Pei Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. JAMA Network Open 2024, 7: e2351062. PMID: 38241048, PMCID: PMC10799264, DOI: 10.1001/jamanetworkopen.2023.51062.Peer-Reviewed Original ResearchConceptsCardiac toxic effectsMediastinal RTHodgkin lymphomaRadiation therapyCumulative incidenceCardiac diseaseDoxorubicin doseCohort studyClinical trialsMedian mean heart doseChildren's Oncology Group clinical trialStudy populationHigh-risk HLMean heart dosePlanned cumulative doseRadiation therapy useIncidence of cardiac diseaseCumulative doxorubicin doseRisks associated with treatmentNorth American trialsGroup clinical trialFollow-up guidelinesStandard treatment groupToxic effectsMaintained long term
2023
Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831
Lo A, Lee I, Pei Q, Wu Y, McCarten K, Hoppe B, Hodgson D, Roberts K, Milgrom S, Kessel S, Cole P, Kelly K, Cho S. Prognostic value of chest x‐ray‐ and CT‐defined large mediastinal adenopathy in high‐risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatric Blood & Cancer 2023, 70: e30452. PMID: 37243975, PMCID: PMC10546608, DOI: 10.1002/pbc.30452.Peer-Reviewed Original ResearchConceptsRelapse-free survivalLarge mediastinal adenopathySlow early responseInferior relapse-free survivalWorse relapse-free survivalMediastinal mass ratioPediatric Hodgkin lymphomaHodgkin's lymphomaMediastinal adenopathyPrognostic valueAdvanced-stage HL patientsChildren's Oncology Group studyChest X-rayHazard ratioHL patientsMedian agePoor prognosisChest radiographsMass volumeMass diameterPatientsML/Group studyCTEarly response
2019
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. British Journal Of Haematology 2019, 187: 39-48. PMID: 31180135, PMCID: PMC6857800, DOI: 10.1111/bjh.16014.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCyclophosphamideDoxorubicinDrug Administration ScheduleDrug MonitoringEtoposideFemaleHodgkin DiseaseHumansIfosfamideMaleNeoplasm StagingPositron-Emission TomographyPrednisoneProspective StudiesRadiotherapy, AdjuvantRecurrenceTreatment OutcomeVincristineVinorelbineYoung AdultConceptsHigh-risk Hodgkin lymphomaABVE-PCOncology GroupHodgkin's lymphomaEarly respondersRapid early respondersEnd of chemotherapyEvent-free survivalOverall survival rateResponse-adapted therapyChildren's Oncology GroupTreatment of childrenPET-positive lesionsAlkylator exposureOS ratesActive diseaseTreat analysisPediatric patientsRadiotherapy volumeClinical evidenceEarly progressionRadiation volumeRecent trialsPositive lesionsSER patients
2016
Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children
Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology 2016, 2: 1574-1581. PMID: 27491009, DOI: 10.1001/jamaoncol.2016.2547.Peer-Reviewed Original ResearchConceptsPostoperative radiotherapyOverall survivalMultivariable logistic regressionNational Cancer Data BaseLogistic regressionAdjuvant chemotherapy strategyLow facility volumeNational treatment patternsMultivariable Cox regressionLong-term morbidityYear of diagnosisDay of surgeryKaplan-Meier analysisNational database analysisPoor overall survivalLog-rank testYoung childrenAge 3Adjuvant chemotherapyRadiotherapy patternsRadiotherapy utilizationWorse survivalDistant metastasisMultivariable analysisTreatment patterns
2014
ACR appropriateness Criteria® pediatric Hodgkin lymphoma
Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, Hoppe BS, Ng A, Roberts KB, Shapiro R, Wilder RB, Yunes MJ, Constine LS. ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer 2014, 61: 1305-1312. PMID: 24616347, DOI: 10.1002/pbc.24983.Peer-Reviewed Original ResearchConceptsPediatric Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAppropriateness of imagingACR Appropriateness CriteriaExpert panelMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesCommon clinical scenariosSpecific clinical conditionsCurrent medical literaturePotential long-term effectsCurable malignancyExpert medical opinionClinical variantsClinical conditionsLong-term effectsAmerican CollegeClinical careTherapy needTreatment approachesGuideline developmentClinical scenariosLymphoma
2012
Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008
Jairam V, Roberts KB, Yu JB. Historical Trends in the Use of Radiation Therapy for Pediatric Cancers: 1973-2008. International Journal Of Radiation Oncology • Biology • Physics 2012, 85: e151-e155. PMID: 23273995, PMCID: PMC3636568, DOI: 10.1016/j.ijrobp.2012.10.007.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone NeoplasmsChildChild, PreschoolFemaleHodgkin DiseaseHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMaleNeoplasmsNeuroblastomaOsteosarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRadiotherapyRetinoblastomaSEER ProgramSoft Tissue NeoplasmsTime FactorsUnited StatesWilms TumorYoung AdultConceptsUse of RTSoft tissue cancerNon-Hodgkin lymphomaRT useAcute lymphoblastic leukemiaAcute myeloid leukemiaRadiation therapyHodgkin's lymphomaLymphoblastic leukemiaMyeloid leukemiaWilms tumorBrain cancerNational Cancer Institute's SurveillanceExternal beam radiation therapyEnd Results (SEER) databasePercentage of patientsSEER 9 databaseBeam radiation therapyTumor RegistryInitial treatmentResults databaseCombination therapyDiagnosis groupsPediatric cancerJoint cancerPatterns of subsequent malignancies after Hodgkin lymphoma in children and adults
Omer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.Peer-Reviewed Original ResearchConceptsSecond malignant neoplasmsStandardized incidence ratiosSolid second malignant neoplasmsExtended field radiotherapyRecent treatment optionsLow-dose radiationSMN riskSubsequent malignanciesModality therapyIncidence ratiosHodgkin's lymphomaTreatment optionsMalignant neoplasmsSubgroup analysisCMT groupLower incidenceHigh riskGeneral populationAlkylator chemotherapyPatientsDose radiationRiskRadiotherapyChildrenAdults
2011
Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis
Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2011, 118: 4212-4219. PMID: 22213196, DOI: 10.1002/cncr.27373.Peer-Reviewed Original ResearchConceptsAtypical teratoid rhabdoid tumorMedian overall survivalOverall survivalRT useLandmark analysisRhabdoid tumorRare central nervous system malignanciesNational Cancer Institute's SurveillanceCentral nervous system malignanciesCox proportional hazards modelRole of radiotherapyEnd Results (SEER) databaseEnd Results analysisSignificant survival benefitProspective clinical trialsGross total resectionPatients ages 4Nervous system malignanciesImmortal time biasProportional hazards modelLong-term survivorshipAdjuvant radiotherapyInitial radiotherapyPrimary endpointInitial managementKilovoltage Imaging Doses in the Radiotherapy of Pediatric Cancer Patients
Deng J, Chen Z, Roberts KB, Nath R. Kilovoltage Imaging Doses in the Radiotherapy of Pediatric Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: 1680-1688. PMID: 21477943, DOI: 10.1016/j.ijrobp.2011.01.062.Peer-Reviewed Original ResearchConceptsPediatric cancer patientsCancer patientsTesticular shieldingSpinal cordKilovoltage cone-beamCBCT dosesMean dosesClinical conditionsDose reductionLarge dosesFemoral headPatientsCBCT scansCone beamDosesFull-fan modeOptical nerveCBCT fieldCordDose increaseImaging dosesScanning protocolOARsRadiotherapyHalf-fan mode
1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program